^
Association details:
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
Title:

Patterns of Response to Immune Checkpoint Inhibitors in Association with Genomic and Clinical Features in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC)

Published date:
01/14/2021
Excerpt:
HPD was observed in 15.4 % of patients with R/M HNSCC treated with IO and was associated with worse PFS and OS. EGFR amplification was identified in patients with HPD.
DOI:
10.3390/cancers13020286